全文获取类型
| 收费全文 | 28443篇 |
| 免费 | 2114篇 |
| 国内免费 | 121篇 |
专业分类
| 耳鼻咽喉 | 233篇 |
| 儿科学 | 832篇 |
| 妇产科学 | 609篇 |
| 基础医学 | 3636篇 |
| 口腔科学 | 490篇 |
| 临床医学 | 2745篇 |
| 内科学 | 6982篇 |
| 皮肤病学 | 512篇 |
| 神经病学 | 2902篇 |
| 特种医学 | 1131篇 |
| 外国民族医学 | 8篇 |
| 外科学 | 4437篇 |
| 综合类 | 258篇 |
| 一般理论 | 2篇 |
| 预防医学 | 1695篇 |
| 眼科学 | 425篇 |
| 药学 | 1852篇 |
| 中国医学 | 22篇 |
| 肿瘤学 | 1907篇 |
出版年
| 2023年 | 141篇 |
| 2022年 | 195篇 |
| 2021年 | 654篇 |
| 2020年 | 328篇 |
| 2019年 | 655篇 |
| 2018年 | 754篇 |
| 2017年 | 539篇 |
| 2016年 | 527篇 |
| 2015年 | 648篇 |
| 2014年 | 973篇 |
| 2013年 | 1193篇 |
| 2012年 | 1885篇 |
| 2011年 | 1938篇 |
| 2010年 | 1044篇 |
| 2009年 | 997篇 |
| 2008年 | 1571篇 |
| 2007年 | 1578篇 |
| 2006年 | 1594篇 |
| 2005年 | 1451篇 |
| 2004年 | 1442篇 |
| 2003年 | 1231篇 |
| 2002年 | 1166篇 |
| 2001年 | 579篇 |
| 2000年 | 486篇 |
| 1999年 | 523篇 |
| 1998年 | 246篇 |
| 1997年 | 220篇 |
| 1996年 | 201篇 |
| 1995年 | 168篇 |
| 1994年 | 185篇 |
| 1993年 | 138篇 |
| 1992年 | 390篇 |
| 1991年 | 353篇 |
| 1990年 | 346篇 |
| 1989年 | 346篇 |
| 1988年 | 285篇 |
| 1987年 | 292篇 |
| 1986年 | 278篇 |
| 1985年 | 284篇 |
| 1984年 | 210篇 |
| 1983年 | 173篇 |
| 1979年 | 217篇 |
| 1978年 | 157篇 |
| 1977年 | 145篇 |
| 1975年 | 158篇 |
| 1974年 | 179篇 |
| 1973年 | 148篇 |
| 1972年 | 167篇 |
| 1971年 | 132篇 |
| 1970年 | 131篇 |
排序方式： 共有10000条查询结果，搜索用时 31 毫秒
1.
2.
3.
4.
Joseph F. Levy Rahul Khairnar Alexander V. Louie Timothy N. Showalter C. Daniel Mullins Mark V. Mishra 《Practical radiation oncology》2019,9(2):e172-e179
Purpose
A hydrogel rectal spacer (HRS) is a medical device that is approved by the U.S. Food and Drug Administration to increase the separation between the prostate and rectum. We conducted a cost-effectiveness analysis of HRS use for reduction in radiation therapy (RT) toxicities in patients with prostate cancer (PC) undergoing external beam RT (EBRT).Methods and Materials
A multistate Markov model was constructed from the U.S. payer perspective to examine the cost-effectiveness of HRS in men with localized PC receiving EBRT (EBRT alone vs EBRT + HRS). The subgroups analyzed included site of HRS placement (hospital outpatient, physician office, ambulatory surgery center) and proportion of patients with good baseline erectile function (EF). Data on EF, gastrointestinal and genitourinary toxicities incidence, and potential risks associated with HRS implantation were obtained from a recently published randomized clinical trial. Health utilities and costs were derived from the literature and the 2018 Physician Fee Schedule and were discounted 3% annually. Quality-adjusted life years (QALYs) and costs were modeled for a 5-year period from receipt of RT. Probabilistic sensitivity analysis and value-based threshold analyses were conducted.Results
The per-patient 5-year incremental cost for spacers administered in a hospital outpatient setting was $3578, and the incremental effectiveness was 0.0371 QALYs. The incremental cost-effectiveness ratio was $96,440/QALY for patients with PC undergoing HRS insertion in a hospital and $39,286/QALY for patients undergoing HRS insertion in an ambulatory facility. For men with good baseline EF, the incremental cost-effectiveness ratio was $35,548/QALY and $9627/QALY in hospital outpatient and ambulatory facility settings, respectively.Conclusions
Based on the current Medicare Physician Fee Schedule, HRS is cost-effective at a willingness to pay threshold of $100,000. These results contain substantial uncertainty, suggesting more evidence is needed to refine future decision-making. 相似文献5.
6.
7.
8.
9.
10.
Thierry Patrice David Olivier Ludovic Bourre 《Journal of environmental pathology, toxicology and oncology》2006,25(1-2):467-485
Photodynamic therapy (PDT) is based on the selective light activation of an exogenously given drug to patients. PDT acts mainly on cell membranes either of neovascular endothelial cells or of cancer cells leading to cancer cell death. Six drugs are now marketed based on clinical assays in various indications, which showed a clear cost efficiency as compared to other classical procedures. PDT is easy to handle and can be performed in medical installations fitting the conditions of health care in developing countries. Its cost effectiveness could represent an appropriate solution to the increasing number of cancers of various origin. However despite all the clinical results now available, PDT development remains slow. The reasons for this situation include cost of development, intellectual property, and competition between pharmaceutical companies. 相似文献